Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation

• Status: Recruiting
• Trial end date: 2028-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This phase II trial studies how well contrast-enhanced ultrasound (CEUS) works for diagnosing patients with renal cell cancer (RCC) that has come back (recurrent) after an ablation. Diagnostic imaging, such as CEUS, may help find and monitor long term renal cell cancer recurrence following cryo or microwave ablation.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Thomas Jefferson University

Criteria

Inclusion Criteria:

• Previously received cryotherapy or microwave therapy of RCC

• Has available contrast enhanced (CE)-MRI or CE-CT imaging prior to ablative therapy

• Have previously had or are scheduled to have a contrast-enhanced MRI/CT for the monitoring of RCC recurrence within 2 weeks of the CEUS study

• Be at least 18 years of age

• Be medically stable

• If a female of child-bearing age, must have a negative pregnancy test

• Have signed Informed Consent to participate in the study

Exclusion Criteria:

• Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable

• Patients with known sensitivities to the components of Lumason

• Patients with severe emphysema, pulmonary vasculitis, or a history of pulmonary emboli